Digestive Diseases and Sciences

, Volume 59, Issue 12, pp 2890–2904 | Cite as

Targeting Apoptosis in Autoimmune Hepatitis



Apoptosis is the predominant mechanism of liver cell death in autoimmune hepatitis, and interventions that can modulate this activity are emerging. The aim of this review was to describe the apoptotic mechanisms, possible aberrations, and opportunities for intervention in autoimmune hepatitis. Studies cited in PubMed from 1972 to 2014 for autoimmune hepatitis, apoptosis in liver disease, apoptosis mechanisms, and apoptosis treatment were examined. Apoptosis is overactive in autoimmune hepatitis, and the principal pathway of cell death is receptor mediated. Surface death receptors are activated by extrinsic factors including liver-infiltrating cytotoxic T cells and the cytokine milieu. The executioner caspases 3 and 7 cleave nuclear deoxyribonucleic acid, and the release of apoptotic bodies can stimulate inflammatory, immune, and fibrotic responses. Changes in mitochondrial membrane permeability can be initiated by caspase 8, and an intrinsic pathway of apoptosis can complement the extrinsic pathway. Defects in the apoptosis of activated effector cells can prolong their survival and sustain the immune response. Caspase inhibitors have been used in diverse experimental and human diseases to retard apoptosis. Oligonucleotides that inhibit the signaling of toll-like receptors can limit the presentation of auto-antigens, and inhibitors of apoptosis that extend the survival of effector cells can be blocked by antisense oligonucleotides. Mechanisms that enhance the clearance of apoptotic bodies and affect key signaling pathways are also feasible. Interventions that influence the survival of liver and effector cells by altering their apoptosis are candidates for study in autoimmune hepatitis.


Autoimmune hepatitis Pathogenesis Apoptosis Interventions 


Conflict of interest



  1. 1.
    Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.PubMedGoogle Scholar
  2. 2.
    Kerr JF, Cooksley WG, Searle J, et al. The nature of piecemeal necrosis in chronic active hepatitis. Lancet. 1979;2:827–828.PubMedGoogle Scholar
  3. 3.
    Dong Z, Saikumar P, Weinberg JM, Venkatachalam MA. Internucleosomal DNA cleavage triggered by plasma membrane damage during necrotic cell death. Involvement of serine but not cysteine proteases. Am J Pathol. 1997;151:1205–1213.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Afford S, Randhawa S. Apoptosis. Mol Pathol. 2000;53:55–63.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113–128.PubMedGoogle Scholar
  6. 6.
    Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–257.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Kerr JF. Shrinkage necrosis: a distinct mode of cellular death. J Pathol. 1971;105:13–20.PubMedGoogle Scholar
  8. 8.
    Wyllie AH, Morris RG, Smith AL, Dunlop D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol. 1984;142:67–77.PubMedGoogle Scholar
  9. 9.
    Berg CP, Stein GM, Keppeler H, et al. Apoptosis-associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis. Apoptosis. 2008;13:63–75.PubMedGoogle Scholar
  10. 10.
    Zampieri S, Degen W, Ghiradello A, Doria A, van Venrooij WJ. Dephosphorylation of autoantigenic ribosomal P proteins during Fas-L induced apoptosis: a possible trigger for the development of the autoimmune response in patients with systemic lupus erythematosus. Ann Rheum Dis. 2001;60:72–76.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Greidinger EL, Foecking MF, Ranatunga S, Hoffman RW. Apoptotic U1-70 kd is antigenically distinct from the intact form of the U1-70-kd molecule. Arthritis Rheum. 2002;46:1264–1269.PubMedGoogle Scholar
  12. 12.
    Dieker JW, Fransen JH, van Bavel CC, et al. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum. 2007;56:1921–1933.PubMedGoogle Scholar
  13. 13.
    Rosen A, Casciola-Rosen L. Autoantigens in systemic autoimmunity: critical partner in pathogenesis. J Intern Med. 2009;265:625–631.PubMedCentralPubMedGoogle Scholar
  14. 14.
    Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407:784–788.PubMedGoogle Scholar
  15. 15.
    Grimsley C, Ravichandran KS. Cues for apoptotic cell engulfment: eat-me, don’t eat-me and come-get-me signals. Trends Cell Biol. 2003;13:648–656.PubMedGoogle Scholar
  16. 16.
    Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol. 2006;27:244–250.PubMedGoogle Scholar
  17. 17.
    A-Gonzalez N, Bensinger SJ, Hong C, et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity. 2009;31:245–258.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309–1312.PubMedGoogle Scholar
  19. 19.
    Kanzler S, Galle PR. Apoptosis and the liver. Semin Cancer Biol. 2000;10:173–184.PubMedGoogle Scholar
  20. 20.
    Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology. 2003;38:1188–1198.PubMedGoogle Scholar
  21. 21.
    Zhan SS, Jiang JX, Wu J, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology. 2006;43:435–443.PubMedGoogle Scholar
  22. 22.
    Ogawa S, Sakaguchi K, Takaki A, et al. Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ T cells in peripheral blood derived from patients with autoimmune hepatitis or chronic hepatitis C with autoimmune phenomena. J Gastroenterol Hepatol. 2000;15:69–75.PubMedGoogle Scholar
  23. 23.
    Fox CK, Furtwaengler A, Nepomuceno RR, Martinez OM, Krams SM. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver. 2001;21:272–279.PubMedGoogle Scholar
  24. 24.
    Bai J, Odin JA. Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun Rev. 2003;2:36–42.PubMedGoogle Scholar
  25. 25.
    Patel T, Gores GJ. Apoptosis and hepatobiliary disease. Hepatology. 1995;21:1725–1741.PubMedGoogle Scholar
  26. 26.
    Thatte U, Dahanukar S. Apoptosis: clinical relevance and pharmacological manipulation. Drugs. 1997;54:511–532.PubMedGoogle Scholar
  27. 27.
    D’Amelio M, Tino E, Cecconi F. The apoptosome: emerging insights and new potential targets for drug design. Pharm Res. 2008;25:740–751.PubMedCentralPubMedGoogle Scholar
  28. 28.
    O’Reilly LA, Strasser A. Apoptosis and autoimmune disease. Inflamm Res. 1999;48:5–21.PubMedGoogle Scholar
  29. 29.
    Neuman MG. Apoptosis in diseases of the liver. Crit Rev Clin Lab Sci. 2001;38:109–166.PubMedGoogle Scholar
  30. 30.
    Beland K, Lapierre P, Djilali-Saiah I, Alvarez F. Liver restores immune homeostasis after local inflammation despite the presence of autoreactive T cells. PLoS One. 2012;7:e48192.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol. 2000;2:156–162.PubMedGoogle Scholar
  32. 32.
    Tsujimoto Y, Nakagawa T, Shimizu S. Mitochondrial membrane permeability transition and cell death. Biochim Biophys Acta. 2006;1757:1297–1300.PubMedGoogle Scholar
  33. 33.
    Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–1326.PubMedGoogle Scholar
  34. 34.
    Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87:99–163.PubMedGoogle Scholar
  35. 35.
    Ren D, Tu HC, Kim H, et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science. 2010;330:1390–1393.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Ekert PG, Read SH, Silke J, et al. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J Cell Biol. 2004;165:835–842.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Rodriguez J, Lazebnik Y. Caspase-9 and APAF-1 form an active holoenzyme. Genes Dev. 1999;13:3179–3184.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Semin Liver Dis. 2010;30:402–410.PubMedCentralPubMedGoogle Scholar
  39. 39.
    Faubion WA, Gores GJ. Death receptors in liver biology and pathobiology. Hepatology. 1999;29:1–4.PubMedGoogle Scholar
  40. 40.
    Desbarats J, Duke RC, Newell MK. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med. 1998;4:1377–1382.PubMedGoogle Scholar
  41. 41.
    Nagata S. Apoptosis mediated by the Fas system. Prog Mol Subcell Biol. 1996;16:87–103.PubMedGoogle Scholar
  42. 42.
    Wajant H. Death receptors. Essays Biochem. 2003;39:53–71.PubMedGoogle Scholar
  43. 43.
    Oberst A, Pop C, Tremblay AG, et al. Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation. J Biol Chem. 2010;285:16632–16642.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003;10:26–35.PubMedGoogle Scholar
  45. 45.
    Fuentes-Prior P, Salvesen GS. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J. 2004;384:201–232.PubMedCentralPubMedGoogle Scholar
  46. 46.
    Ma S, Hockings C, Anwari K, et al. Assembly of the Bak apoptotic pore: a critical role for the Bak protein alpha6 helix in the multimerization of homodimers during apoptosis. J Biol Chem. 2013;288:26027–26038.PubMedCentralPubMedGoogle Scholar
  47. 47.
    Grenet J, Teitz T, Wei T, Valentine V, Kidd VJ. Structure and chromosome localization of the human CASP8 gene. Gene. 1999;226:225–232.PubMedGoogle Scholar
  48. 48.
    Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA. 2001;98:13884–13888.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Muhlethaler-Mottet A, Flahaut M, Bourloud KB, et al. Individual caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis. Cell Death Dis. 2011;2:e125.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Kischkel FC, Lawrence DA, Tinel A, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem. 2001;276:46639–46646.PubMedGoogle Scholar
  51. 51.
    Sprick MR, Rieser E, Stahl H, et al. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002;21:4520–4530.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Fischer U, Stroh C, Schulze-Osthoff K. Unique and overlapping substrate specificities of caspase-8 and caspase-10. Oncogene. 2006;25:152–159.PubMedGoogle Scholar
  53. 53.
    Wachmann K, Pop C, van Raam BJ, et al. Activation and specificity of human caspase-10. Biochemistry. 2010;49:8307–8315.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Kahraman A, Gerken G, Canbay A. Apoptosis in immune-mediated liver diseases. Dig Dis. 2010;28:144–149.PubMedGoogle Scholar
  55. 55.
    Kahraman A, Fingas CD, Syn WK, Gerken G, Canbay A. Role of stress-induced NKG2D ligands in liver diseases. Liver Int. 2012;32:370–382.PubMedGoogle Scholar
  56. 56.
    Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol. 2014;20:2515–2532.PubMedCentralPubMedGoogle Scholar
  57. 57.
    Czaja AJ. Review article: Chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. Aliment Pharmacol Ther. 2014;40:261–279.Google Scholar
  58. 58.
    Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004;39:273–278.PubMedGoogle Scholar
  59. 59.
    Bechmann LP, Jochum C, Kocabayoglu P, et al. Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol. 2010;53:639–647.PubMedGoogle Scholar
  60. 60.
    Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759–1762.PubMedGoogle Scholar
  61. 61.
    Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995;154:2706–2713.PubMedGoogle Scholar
  62. 62.
    Eichhorst ST. Modulation of apoptosis as a target for liver disease. Expert Opin Ther Targets. 2005;9:83–99.PubMedGoogle Scholar
  63. 63.
    Hiraide A, Imazeki F, Yokosuka O, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005;100:1322–1329.PubMedGoogle Scholar
  64. 64.
    Inazawa J, Itoh N, Abe T, Nagata S. Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics. 1992;14:821–822.PubMedGoogle Scholar
  65. 65.
    Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007;69:227–235.PubMedGoogle Scholar
  66. 66.
    Ichiki Y, Aoki CA, Bowlus CL, et al. T cell immunity in autoimmune hepatitis. Autoimmun Rev. 2005;4:315–321.PubMedGoogle Scholar
  67. 67.
    Zipp F, Weller M, Calabresi PA, et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann Neurol. 1998;43:116–120.PubMedGoogle Scholar
  68. 68.
    Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol. 2005;6:386–398.PubMedGoogle Scholar
  69. 69.
    Jodo S, Kobayashi S, Kayagaki N, et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol. 1997;107:89–95.PubMedCentralPubMedGoogle Scholar
  70. 70.
    Fujihara T, Takeuchi T, Tsubota K, et al. Serum soluble Fas/APO-1 is increased in patients with primary Sjogren’s syndrome. Clin Rheumatol. 1998;17:496–499.PubMedGoogle Scholar
  71. 71.
    Jodo S, Kobayashi S, Nakajima Y, et al. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol. 1998;112:166–171.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 1996;56:3870–3874.PubMedGoogle Scholar
  73. 73.
    Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res. 1999;5:3529–3533.PubMedGoogle Scholar
  74. 74.
    Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res. 2001;7:1282–1286.PubMedGoogle Scholar
  75. 75.
    Wyllie AH, Arends MJ, Morris RG, Walker SW, Evan G. The apoptosis endonuclease and its regulation. Semin Immunol. 1992;4:389–397.PubMedGoogle Scholar
  76. 76.
    Wyllie AH. Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer. 1993;67:205–208.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Ochi M, Ohdan H, Mitsuta H, et al. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology. 2004;39:1321–1331.PubMedGoogle Scholar
  78. 78.
    Kahraman A, Schlattjan M, Kocabayoglu P, et al. Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology. 2010;51:92–102.PubMedGoogle Scholar
  79. 79.
    Kohga K, Takehara T, Tatsumi T, et al. Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci. 2008;99:1643–1649.PubMedGoogle Scholar
  80. 80.
    Holdenrieder S, Eichhorn P, Beuers U, et al. Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res. 2007;27:2041–2045.PubMedGoogle Scholar
  81. 81.
    Norris S, Kondeatis E, Collins R, et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology. 2001;120:1475–1482.PubMedGoogle Scholar
  82. 82.
    Cox ST, Madrigal JA, Saudemont A. Diversity and characterization of polymorphic 5′ promoter haplotypes of MICA and MICB genes. Tissue Antigens. 2014. doi: 10.1111/tan.12400.
  83. 83.
    Hill MM, Adrain C, Duriez PJ, Creagh EM, Martin SJ. Analysis of the composition, assembly kinetics and activity of native Apaf-1 apoptosomes. EMBO J. 2004;23:2134–2145.PubMedCentralPubMedGoogle Scholar
  84. 84.
    Miyazaki K, Yoshida H, Sasaki M, et al. Caspase-independent cell death and mitochondrial disruptions observed in the Apaf1-deficient cells. J Biochem. 2001;129:963–969.PubMedGoogle Scholar
  85. 85.
    Riedl SJ, Li W, Chao Y, Schwarzenbacher R, Shi Y. Structure of the apoptotic protease-activating factor 1 bound to ADP. Nature. 2005;434:926–933.PubMedGoogle Scholar
  86. 86.
    Pop C, Timmer J, Sperandio S, Salvesen GS. The apoptosome activates caspase-9 by dimerization. Mol Cell. 2006;22:269–275.PubMedGoogle Scholar
  87. 87.
    Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J. 2000;19:4310–4322.PubMedCentralPubMedGoogle Scholar
  88. 88.
    Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol. 2000;2:476–483.PubMedGoogle Scholar
  89. 89.
    Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest. 2005;115:2633–2639.PubMedCentralPubMedGoogle Scholar
  90. 90.
    Chandra D, Bratton SB, Person MD, et al. Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosome. Cell. 2006;125:1333–1346.PubMedGoogle Scholar
  91. 91.
    Pop C, Salvesen GS. Human caspases: activation, specificity, and regulation. J Biol Chem. 2009;284:21777–21781.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ. 2006;13:179–188.PubMedGoogle Scholar
  93. 93.
    Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006;7:988–994.PubMedCentralPubMedGoogle Scholar
  94. 94.
    Pathan N, Marusawa H, Krajewska M, et al. TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer. J Biol Chem. 2001;276:32220–32229.PubMedGoogle Scholar
  95. 95.
    Yamamoto M, Torigoe T, Kamiguchi K, et al. A novel isoform of TUCAN is overexpressed in human cancer tissues and suppresses both caspase-8- and caspase-9-mediated apoptosis. Cancer Res. 2005;65:8706–8714.PubMedGoogle Scholar
  96. 96.
    Verhagen AM, Silke J, Ekert PG, et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J Biol Chem. 2002;277:445–454.PubMedGoogle Scholar
  97. 97.
    Sharief MK, Noori MA, Zoukos Y. Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-beta therapy. J Neuroimmunol. 2002;129:224–231.PubMedGoogle Scholar
  98. 98.
    Waiczies S, Weber A, Lunemann JD, et al. Elevated Bcl-X(L) levels correlate with T cell survival in multiple sclerosis. J Neuroimmunol. 2002;126:213–220.PubMedGoogle Scholar
  99. 99.
    Semra YK, Seidi OA, Sharief MK. Disease activity in multiple sclerosis correlates with T lymphocyte expression of the inhibitor of apoptosis proteins. J Neuroimmunol. 2002;122:159–166.PubMedGoogle Scholar
  100. 100.
    Semra YK, Seidi OA, Sharief MK. Overexpression of the apoptosis inhibitor FLIP in T cells correlates with disease activity in multiple sclerosis. J Neuroimmunol. 2001;113:268–274.PubMedGoogle Scholar
  101. 101.
    Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol. 2010;42:210–213.PubMedGoogle Scholar
  102. 102.
    Safa AR. c-FLIP, a master anti-apoptotic regulator. Exp Oncol. 2012;34:176–184.PubMedGoogle Scholar
  103. 103.
    Piao X, Komazawa-Sakon S, Nishina T, et al. c-FLIP maintains tissue homeostasis by preventing apoptosis and programmed necrosis. Sci Signal. 2012;5:ra93.PubMedGoogle Scholar
  104. 104.
    Bona G, Defranco S, Chiocchetti A, et al. Defective function of Fas in T cells from paediatric patients with autoimmune thyroid diseases. Clin Exp Immunol. 2003;133:430–437.PubMedCentralPubMedGoogle Scholar
  105. 105.
    Masuichi H, Seki S, Kitada T, et al. Significant role of apoptosis in type-1 autoimmune hepatitis. Osaka City Med J. 1999;45:61–79.PubMedGoogle Scholar
  106. 106.
    Canbay A, Taimr P, Torok N, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest. 2003;83:655–663.PubMedGoogle Scholar
  107. 107.
    Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–1669.PubMedCentralPubMedGoogle Scholar
  108. 108.
    Czaja AJ. Review article: Prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther. 2014;39:385–406.PubMedGoogle Scholar
  109. 109.
    Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002;2:965–975.PubMedGoogle Scholar
  110. 110.
    Canbay A, Higuchi H, Bronk SF, et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology. 2002;123:1323–1330.PubMedGoogle Scholar
  111. 111.
    Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther. 2004;308:1191–1196.PubMedGoogle Scholar
  112. 112.
    Takehara T, Tatsumi T, Suzuki T, et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology. 2004;127:1189–1197.PubMedGoogle Scholar
  113. 113.
    Tsikrikoni A, Kyriakou DS, Rigopoulou EI, et al. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol. 2005;42:393–399.PubMedGoogle Scholar
  114. 114.
    Taylor PR, Martinez-Pomares L, Stacey M, et al. Macrophage receptors and immune recognition. Ann Rev Immunol. 2005;23:901–944.Google Scholar
  115. 115.
    Leitinger N. The role of phospholipid oxidation products in inflammatory and autoimmune diseases: evidence from animal models and in humans. Subcell Biochem. 2008;49:325–350.PubMedGoogle Scholar
  116. 116.
    Hanayama R, Tanaka M, Miwa K, et al. Identification of a factor that links apoptotic cells to phagocytes. Nature. 2002;417:182–187.PubMedGoogle Scholar
  117. 117.
    Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol. 2007;7:964–974.PubMedGoogle Scholar
  118. 118.
    Lemke G, Burstyn-Cohen T. TAM receptors and the clearance of apoptotic cells. Ann NY Acad Sci. 2010;1209:23–29.PubMedCentralPubMedGoogle Scholar
  119. 119.
    Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003;9:213–219.PubMedGoogle Scholar
  120. 120.
    Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol. 2004;20:455–480.PubMedGoogle Scholar
  121. 121.
    Rong GH, Yang GX, Ando Y, et al. Human intrahepatic biliary epithelial cells engulf blebs from their apoptotic peers. Clin Exp Immunol. 2013;172:95–103.PubMedCentralPubMedGoogle Scholar
  122. 122.
    Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461:282–286.PubMedCentralPubMedGoogle Scholar
  123. 123.
    Dranoff JA, Ogawa M, Kruglov EA, et al. Expression of P2Y nucleotide receptors and ectonucleotidases in quiescent and activated rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2004;287:G417–G424.PubMedGoogle Scholar
  124. 124.
    Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells. Cell. 2010;140:619–630.PubMedGoogle Scholar
  125. 125.
    Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity. 2008;28:468–476.PubMedGoogle Scholar
  126. 126.
    Sun EW, Shi YF. Apoptosis: the quiet death silences the immune system. Pharmacol Ther. 2001;92:135–145.PubMedGoogle Scholar
  127. 127.
    Ghavami S, Hashemi M, Kadkhoda K, et al. Apoptosis in liver diseases—detection and therapeutic applications. Med Sci Monit. 2005;11:RA337–RA345.PubMedGoogle Scholar
  128. 128.
    Sun H, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J Med Chem. 2004;47:4147–4150.PubMedGoogle Scholar
  129. 129.
    Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738–4745.PubMedGoogle Scholar
  130. 130.
    O’Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007;25:1114–1120.PubMedGoogle Scholar
  131. 131.
    Masuoka HC, Guicciardi ME, Gores GJ. Caspase inhibitors for the treatment of hepatitis C. Clin Liver Dis. 2009;13:467–475.PubMedCentralPubMedGoogle Scholar
  132. 132.
    Hoglen NC, Hirakawa BP, Fisher CD, et al. Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury. J Pharmacol Exp Ther. 2001;297:811–818.PubMedGoogle Scholar
  133. 133.
    Ueno Y, Ohmi T, Yamamoto M, et al. Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. J Pharmacol Sci. 2007;105:201–205.PubMedGoogle Scholar
  134. 134.
    Witek RP, Stone WC, Karaca FG, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology. 2009;50:1421–1430.PubMedGoogle Scholar
  135. 135.
    Anstee QM, Concas D, Kudo H, et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol. 2010;53:542–550.PubMedGoogle Scholar
  136. 136.
    Yoshida N, Iwata H, Yamada T, et al. Improvement of the survival rate after rat massive hepatectomy due to the reduction of apoptosis by caspase inhibitor. J Gastroenterol Hepatol. 2007;22:2015–2021.PubMedGoogle Scholar
  137. 137.
    Faubel S, Edelstein CL. Caspases as drug targets in ischemic organ injury. Curr Drug Targets Immune Endocr Metab Disord. 2005;5:269–287.Google Scholar
  138. 138.
    Valentino KL, Gutierrez M, Sanchez R, Winship MJ, Shapiro DA. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther. 2003;41:441–449.PubMedGoogle Scholar
  139. 139.
    Pockros PJ, Schiff ER, Shiffman ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007;46:324–329.PubMedGoogle Scholar
  140. 140.
    Arends JE, Hoepelman AI, Nanlohy NM, et al. Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+ T-cells. Apoptosis. 2011;16:959–966.PubMedCentralPubMedGoogle Scholar
  141. 141.
    Baskin-Bey ES, Washburn K, Feng S, et al. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant. 2007;7:218–225.PubMedGoogle Scholar
  142. 142.
    Santiago-Raber ML, Baudino L, Izui S. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun. 2009;33:231–238.PubMedGoogle Scholar
  143. 143.
    Lenert PS. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for toll-like receptors (TLR) 7 and 9. Mediat Inflamm. 2010;2010:986596.Google Scholar
  144. 144.
    LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247–3259.PubMedGoogle Scholar
  145. 145.
    Wang K, Lin B. Inhibitor of apoptosis proteins (IAPs) as regulatory factors of hepatic apoptosis. Cell Signal. 2013;25:1970–1980.PubMedGoogle Scholar
  146. 146.
    Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis. 2001;6:253–261.PubMedGoogle Scholar
  147. 147.
    Zehntner SP, Bourbonniere L, Moore CS, et al. X-linked inhibitor of apoptosis regulates T cell effector function. J Immunol. 2007;179:7553–7560.PubMedGoogle Scholar
  148. 148.
    Jost PJ, Grabow S, Gray D, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature. 2009;460:1035–1039.PubMedCentralPubMedGoogle Scholar
  149. 149.
    Mayer BA, Rehberg M, Erhardt A, et al. Inhibitor of apoptosis proteins as novel targets in inflammatory processes. Arterioscler Thromb Vasc Biol. 2011;31:2240–2250.PubMedGoogle Scholar
  150. 150.
    Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta. 1999;1489:53–68.PubMedGoogle Scholar
  151. 151.
    Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res. 2003;9:2826–2836.PubMedGoogle Scholar
  152. 152.
    Chen J, Xiao XQ, Deng CM, Su XS, Li GY. Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2. J Chemother. 2006;18:525–531.PubMedGoogle Scholar
  153. 153.
    Gorgani NN, Theofilopoulos AN. Contribution of histidine-rich glycoprotein in clearance of immune complexes and apoptotic cells: implications for ameliorating autoimmune diseases. Autoimmunity. 2007;40:260–266.PubMedGoogle Scholar
  154. 154.
    Baker BF, Monia BP. Novel mechanisms for antisense-mediated regulation of gene expression. Biochim Biophys Acta. 1999;1489:3–18.PubMedGoogle Scholar
  155. 155.
    Cui D, Zhang S, Ma J, Han J, Jiang H. Short interfering RNA targeting NF-kappa B induces apoptosis of hepatic stellate cells and attenuates extracellular matrix production. Dig Liver Dis. 2010;42:813–817.PubMedGoogle Scholar
  156. 156.
    Yonehara S. Death receptor Fas and autoimmune disease: from the original generation to therapeutic application of agonistic anti-Fas monoclonal antibody. Cytokine Growth Factor Rev. 2002;13:393–402.PubMedGoogle Scholar
  157. 157.
    Orzaez M, Gortat A, Mondragon L, Perez-Paya E. Peptides and peptide mimics as modulators of apoptotic pathways. ChemMedChem. 2009;4:146–160.PubMedGoogle Scholar
  158. 158.
    Prinz-Hadad H, Mizrachi T, Irony-Tur-Sinai M, et al. Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14.TRAIL. J Neuroinflamm. 2013;10:36.Google Scholar
  159. 159.
    Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034.PubMedCentralPubMedGoogle Scholar
  160. 160.
    Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261–268.PubMedGoogle Scholar
  161. 161.
    Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239–245.PubMedGoogle Scholar
  162. 162.
    Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. 2003;111:363–370.PubMedCentralPubMedGoogle Scholar
  163. 163.
    Sabapathy K. Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci. 2012;106:145–169.PubMedGoogle Scholar
  164. 164.
    Minero VG, Khadjavi A, Costelli P, Baccino FM, Bonelli G. JNK activation is required for TNFalpha-induced apoptosis in human hepatocarcinoma cells. Int Immunopharmacol. 2013;17:92–98.PubMedGoogle Scholar
  165. 165.
    Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology. 2004;39:1066–1074.PubMedGoogle Scholar
  166. 166.
    Holdener M, Hintermann E, Bayer M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med. 2008;205:1409–1422.PubMedCentralPubMedGoogle Scholar
  167. 167.
    Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet. 1995;11:294–300.PubMedGoogle Scholar
  168. 168.
    Yue HH, Diehl GE, Winoto A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ. 2005;12:94–97.PubMedGoogle Scholar
  169. 169.
    Nakamoto Y, Kaneko S, Fan H, et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med. 2002;196:1105–1111.PubMedCentralPubMedGoogle Scholar
  170. 170.
    Pfeffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73:457–467.PubMedGoogle Scholar
  171. 171.
    Tinmouth J, Lee M, Wanless IR, et al. Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver. 2002;22:228–234.PubMedGoogle Scholar
  172. 172.
    Macdonald P, Palmer J, Kirby JA, Jones DE. Apoptosis as a mechanism for cell surface expression of the autoantigen pyruvate dehydrogenase complex. Clini Exp Immunol. 2004;136:559–567.Google Scholar
  173. 173.
    Lleo A, Selmi C, Invernizzi P, et al. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology. 2009;49:871–879.PubMedCentralPubMedGoogle Scholar
  174. 174.
    Lleo A, Bowlus CL, Yang GX, et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology. 2010;52:987–998.PubMedCentralPubMedGoogle Scholar
  175. 175.
    Rong G, Zhong R, Lleo A, et al. Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology. 2011;54:196–203.PubMedCentralPubMedGoogle Scholar
  176. 176.
    Greystoke A, Cummings J, Ward T, et al. Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol. 2008;19:990–995.PubMedGoogle Scholar
  177. 177.
    Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol. 2001;80:230–239.PubMedGoogle Scholar
  178. 178.
    Hiley C, Fryer A, Bell J, Hume R, Strange RC. The human glutathione S-transferases. Immunohistochemical studies of the developmental expression of alpha- and pi-class isoenzymes in liver. Biochem J. 1988;254:255–259.PubMedCentralPubMedGoogle Scholar
  179. 179.
    Denk G, Omary AJ, Reiter FP, et al. sICAM, M30, and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases. Hepatol Res. 2014;. doi: 10.1111/hepr.12304.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Professor Emeritus of Medicine, Division of Gastroenterology and HepatologyMayo Clinic College of MedicineRochesterUSA

Personalised recommendations